What the new research on weight regain after stopping semaglutide actually examined
A team led by Chia Siang Kow, with Kaeshaelya Thiruchelvam, Dinesh Sangarran Ramachandram and colleagues, published a meta-analysis in Endocrinology, Diabetes & Metabolism titled "Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide." Rather than pooling a single endpoint at a single time point, the authors reconstructed aggregate data from previously published trials and fitted a Bayesian longitudinal model — an approach designed to describe the shape of change over time, not just its endpoint.
That distinction matters. Most discussion of stopping a GLP-1 receptor agonist rests on a handful of trial extension phases reporting weight at one follow-up visit. A trajectory model asks a different question: how quickly does weight move after the last dose, does the curve flatten, and does it approach the pre-treatment baseline or settle somewhere below it. The published analysis is indexed in PubMed as a journal article and meta-analysis.
Why discontinuation is the central unresolved question for GLP-1 protocols
Semaglutide, sold as Ozempic for type 2 diabetes and Wegovy for weight management, and tirzepatide, sold as Mounjaro and Zepbound, are injectable incretin drugs. Semaglutide acts on the GLP-1 receptor; tirzepatide acts on both the GLP-1 and GIP receptors. Both work while they are present in the body, and both are labelled as chronic therapies for chronic conditions rather than as time-limited courses.
In practice, people stop for reasons that have nothing to do with clinical intent: cost, insurance denials, supply gaps, side effects, pregnancy planning, or simply reaching a goal weight and wanting to be done. That gap between how the drugs are studied and how they are actually used is why discontinuation research draws outsized attention, and why a modelled trajectory is more useful than a single follow-up number.
It also intersects with the compounded-drug market. When a compounded source disappears or a prescriber changes course, the interruption is unplanned. Understanding the expected direction of travel after a stop is different from being told what to do about it — and none of the new publications tell readers what to do.
If a pause in therapy means restarting later at a different point in a schedule set by your prescriber, the semaglutide dosage calculator is a place to check syringe units against the concentration you actually have on hand.
The ADJUST-T1D extension analysis in Diabetes, Obesity & Metabolism examined glycaemic changes after semaglutide discontinuation in adults with type 1 diabetes using automated insulin delivery. the ADJUST-T1D extension analysis.
What a reconstructed aggregate-data Bayesian analysis can and cannot show
Reconstructed aggregate data means the authors worked backwards from summary statistics and published figures in the source trials to approximate participant-level trajectories. It is a legitimate and increasingly common technique, but it inherits every limitation of the underlying studies: their populations, their follow-up lengths, their attrition, and whatever behavioural support participants received alongside the drug.
A Bayesian longitudinal model produces credible intervals around an estimated curve rather than a single pooled difference. That makes the output easier to interpret as a range of plausible paths and harder to reduce to one headline figure. Readers who see a specific percentage attributed to this paper in secondary coverage should check it against the published article rather than the summary.
The practical caution is that a modelled average is not a personal forecast. Trajectory work describes populations. Individual variation in incretin response is well documented — a case report from Sandro La Vignera and Rosita Angela Condorelli in JCEM Case Reports describes a patient with class 2 obesity who did not respond to tirzepatide and subsequently responded to semaglutide, the kind of divergence a pooled curve cannot capture.
Readers following the head-to-head comparison work who are on the dual-agonist side can use the tirzepatide dosage calculator for the same unit checks.
Separately, an updated systematic review in Annals of Internal Medicine assessed efficacy and safety of GLP-1 receptor agonists and co-agonists for weight loss among adults without diabetes.
What happened when semaglutide was stopped in type 1 diabetes
Published in the same window, an analysis of the ADJUST-T1D extension study appeared in Diabetes, Obesity & Metabolism under the title "Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery," authored by Eslam Montaser, Kanchan Bhasin, Davida Kruger and colleagues. Semaglutide is not approved for type 1 diabetes; its use there is investigational.
The extension design is the informative part. Participants were using automated insulin delivery systems, which continuously adjust insulin based on sensor glucose, so the study had unusually dense glycaemic data through the period after semaglutide was withdrawn. That combination — a closed-loop insulin system plus a withdrawn adjunct drug — offers a clearer picture of what changes and how fast than self-reported measures allow.
Because this is an off-label population in a research setting, the findings should not be read across to weight-management use. They belong to the same broader story: the measurable effects of an incretin drug track with whether it is being taken.
Recording an unplanned interruption as a logged gap rather than a blank stretch is the core idea behind adherence tracking, and it is what makes a later plateau interpretable.
How this fits with the wider incretin evidence published this week
In Annals of Internal Medicine, Ashraf Moiz, Kristian B. Filion, Alexandra E. Samuels and colleagues published an updated systematic review of the efficacy and safety of GLP-1 receptor agonists and co-agonists for weight loss among adults without diabetes. Updated reviews matter because the trial base in this class has grown fast enough that a synthesis from two years ago no longer reflects the available evidence.
Separately, in Clinical Obesity, Giovanna P. Paccola, Rafael F. de Oliveira, Marcelo M. Mochetti and colleagues published a systematic review and meta-analysis restricted to head-to-head studies comparing tirzepatide with semaglutide for weight loss in adults with overweight or obesity. Head-to-head restriction is a methodological choice that avoids comparing across trials with different populations and protocols.
Annals also carried an ACP Journal Club appraisal by Mayer B. Davidson of two-year data on tirzepatide versus intensified conventional care in adults with early uncontrolled type 2 diabetes, reporting reductions in HbA1c and weight. An appraisal is a structured critique of someone else's trial, not new data.
For readers new to the vocabulary used here, our glossary entry on what a protocol is covers how a provider-directed plan differs from an informal routine.
What remains unresolved
None of these publications establish how long an interval away from an incretin drug can be sustained, who is most likely to hold weight after stopping, or whether tapering under clinical supervision changes the trajectory. The trajectory meta-analysis describes what has happened in trials that ended; it does not test a discontinuation strategy against an alternative.
Trials of combination approaches are also multiplying, which will complicate future discontinuation research. Regeneron's Phase 2 programme testing trevogrumab, alone and with garetosmab, alongside semaglutide for lean mass preservation has enrolled 1,005 participants and is listed as active and no longer recruiting. Antag Therapeutics is recruiting 150 participants for a Phase 2 study of AT673 given with semaglutide, and Kailera has a Phase 3 trial of ribupatide against semaglutide and placebo with a planned enrollment of 1,200.
The published trajectory meta-analysis, indexed in PubMed, reconstructed aggregate data from prior trials to model body weight over time after semaglutide or tirzepatide was discontinued. the published trajectory meta-analysis.